Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

被引：108

作者：

FitzGerald, David J. ^{[1
]}

Wayne, Alan S. ^{[2
]}

Kreitman, Robert J. ^{[1
]}

Pastan, Ira ^{[1
]}

机构：

[1] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[2] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

CANCER RESEARCH | 2011年 / 71卷 / 20期

关键词：

ACUTE MYELOID-LEUKEMIA; B-CELL LYMPHOMAS; PHASE-II TRIAL; GEMTUZUMAB OZOGAMICIN; DENILEUKIN DIFTITOX; RFB4(DSFV)-PE38 BL22; CYTOTOXIC ACTIVITY; DIPHTHERIA IMMUNOTOXIN; PEDIATRIC-PATIENTS; CHAIN IMMUNOTOXIN;

D O I：

10.1158/0008-5472.CAN-11-1374

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens. Cancer Res; 71( 20); 6300-9. (C) 2011 AACR.

引用

页码：6300 / 6309

页数：10

共 76 条

[41] A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results. [J].

Kreitman, Robert J. ;

Tallman, Martin S. ;

Coutre, Steven ;

Robak, Tadeusz ;

Wilson, Wyndham H. ;

Stetler-Stevenson, Maryalice ;

Noel, Pierre ;

Fitz-Gerald, David J. ;

Buzoianu, Manuela ;

Lechleider, Robert J. ;

Pastan, Ira .

BLOOD, 2010, 116 (21) :1042-1043

[42] Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P [J].

Kreitman, Robert J. ;

Hassan, Raffit ;

FitzGerald, David J. ;

Pastan, Ira .

CLINICAL CANCER RESEARCH, 2009, 15 (16) :5274-5279

[43] Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia [J].

Kreitman, Robert J. ;

Stetler-Stevenson, Maryalice ;

Margulies, Inger ;

Noel, Pierre ;

FitzGerald, David J. P. ;

Wilson, Wyndham H. ;

Pastan, Ira .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :2983-2990

[44] Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497 [J].

Kuzel, Timothy M. ;

Li, Shuli ;

Eklund, John ;

Foss, Francine ;

Gascoyne, Randy ;

Abramson, Neil ;

Schwerkoske, John F. ;

Weller, Edie ;

Horning, Sandra J. .

LEUKEMIA & LYMPHOMA, 2007, 48 (12) :2397-2402

[45]

Legrand O, 2007, BLOOD, V110, p548A

[46] CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance [J].

Linenberger, ML .

LEUKEMIA, 2005, 19 (02) :176-182

[47] Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study [J].

Lowenberg, Bob ;

Beck, Joachim ;

Graux, Carlos ;

van Putten, Wim ;

Schouten, Harry C. ;

Verdonck, Leo F. ;

Ferrant, Augustin ;

Sonneveld, Pieter ;

Jongen-Lavrencic, Mojca ;

von Lilienfeld-Toal, Marie ;

Biemond, Bart J. ;

Vellenga, Edo ;

Breems, Dimitri ;

de Muijnck, Hilde ;

Schaafsma, Ron ;

Verhoef, Gregor ;

Doehner, Hartmut ;

Gratwohl, Alois ;

Pabst, Thomas ;

Ossenkoppele, Gert J. ;

Maertens, Johan .

BLOOD, 2010, 115 (13) :2586-2591

[48] Antibody-maytansinoid conjugates for the treatment of myeloma [J].

Lutz, Robert J. ;

Whiteman, Kathleen R. .

MABS, 2009, 1 (06) :548-551

[49] Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors [J].

Mansfield, E ;

Amlot, P ;

Pastan, I ;

Fitzgerald, DJ .

BLOOD, 1997, 90 (05) :2020-2026

[50] CHARACTERIZATION OF MURINE AND HUMANIZED ANTI-CD33, GELONIN IMMUNOTOXINS REACTIVE AGAINST MYELOID LEUKEMIAS [J].

MCGRAW, KJ ;

ROSENBLUM, MG ;

CHEUNG, L ;

SCHEINBERG, DA .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, 39 (06) :367-374

← 1 2 3 4 5 6 7 8 →